- Home
- HTD vs ABSI Comparison
HTD vs ABSI Comparison
Compare HTD & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTD | ABSI |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 906.3M | 997.8M |
| IPO Year | 2003 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HTD | ABSI |
|---|---|---|
| Price | $23.47 | $9.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.96 |
| AVG Volume (30 Days) | 48.8K | ★ 2.9M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,534,000.00 |
| Revenue This Year | N/A | $215.96 |
| Revenue Next Year | N/A | $319.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $23.15 | $2.24 |
| 52 Week High | $26.35 | $12.06 |
Technical Indicators
Market Signals| Indicator | HTD | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 14.73 | 60.54 |
| Support Level | $23.22 | $8.55 |
| Resistance Level | $26.02 | $10.03 |
| Average True Range (ATR) | 0.42 | 0.54 |
| MACD | -0.14 | 0.10 |
| Stochastic Oscillator | 0.55 | 82.20 |
Price Performance
Historical ComparisonAbout HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest
John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, convertible bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, communication services, materials, healthcare, real estate, consumer Staples, and short-term investments.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.